The adaptation model of immunity

Immunotherapy

Volumn 6, Issue 1, 2014, Pages 59-70

  Manjili, Masoud H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

APCs; autoimmune diseases; cancer immunotherapy; central tolerance; danger theory; graft versus host disease; immune tolerance; immunity; T cells

Indexed keywords

ADENOSINE TRIPHOSPHATE; CD2 ANTIGEN; CD40 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1;

ADAPTATION; ADAPTIVE IMMUNITY; ANTIGEN RECOGNITION; AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; EFFECTOR CELL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; IMMUNOLOGICAL TOLERANCE; INFECTION; INNATE IMMUNITY; LYMPHOCYTE DIFFERENTIATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MEMORY CELL; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; REVIEW; SOMATIC CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; AUTOANTIGENS; AUTOIMMUNE DISEASES; GENE EXPRESSION REGULATION; HUMANS; IMMUNE TOLERANCE; IMMUNITY; MODELS, IMMUNOLOGICAL; NEOPLASMS;

EID: 84896529056     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.157     Document Type: Review

References (78)

1. Janeway CA Jr. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol. Today 13, 11-16 (2002).
2. Medzhitov R, Janeway CA Jr. How does the immune system distinguish self from nonself? Semin. Immunol. 12, 185-188 (2000).
3. Dumitriu IE, Baruah P, Bianchi ME, Manfredi AA, Rovere-Querini P. Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. Eur. J. Immunol. 35, 2184-2190 (2005).
4. Moser B, Desai DD, Downie MP et al. Receptor for advanced glycation end products expression on T cells contributes to antigen-specific cellular expansion in vivo. J. Immunol. 179, 8051-8058 (2007).
5. Matzinger P. The danger model: a renewed sense of self. Science 296, 301-305 (2002).
6. Pawaria S, Binder RJ. CD91-dependent programming of T-helper cell responses following heat shock protein immunization. Nat. Commun. 2, 521 (2011).
7. Facciponte JG, MacDonald IJ, Wang XY, Kim H, Manjili MH, Subjeck Jr. Heat shock proteins and scavenger receptors: role in adaptive immune responses. Immunol. Invest. 34, 325-342 (2005).
8. Chen XL, Sun L, Guo F et al. High-mobility group box-1 induces proinflammatory cytokines production of Kupffer cells through TLRs-dependent signaling pathway after burn injury. PLoS ONE 7, e50668 (2012).
9. Okamura Y, Watari M, Jerud ES et al. The extra domain A of fibronectin activates Toll-like receptor 4. J. Biol. Chem. 276, 10229-10233 (2011).
10. Obeid M, Tesniere A, Ghiringhelli F et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54-61 (2007).
11. Mutini C, Falzoni S, Ferrari D et al. Mouse dendritic cells express the P2X7 purinergic receptor: characterization and possible participation in antigen presentation. J. Immunol. 163, 1958-1965 (1999).
12. Kariko K, Ni H, Capodici J, Lamphier M, Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. J. Biol. Chem. 279, 12542-12550 (2004).
13. Cavassani KA, Ishii M, Wen H et al. TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events. J. Exp. Med. 205, 2609-2621 (2008).
14. Barrat FJ, Meeker T, Gregorio J et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202, 1131-1139 (2005).
15. Gasse P, Riteau N, Charron S et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am. J. Respir. Crit. Care Med. 179, 903-913 (2009).
16. Babiuk LA, Gomis S, Hecker R. Molecular approaches to disease control. Poult. Sci. 82, 870-875 (2003).
17. Kmieciak M, Morales JK, Morales J, Bolesta E, Grimes M, Manjili MH. Danger signals and nonself entity of tumor antigen are both required for eliciting effective immune responses against HER-2/neu positive mammary carcinoma: implications for vaccine design. Cancer Immunol. Immunother. 57, 1391-1398 (2008).
18. Matzinger P. The evolution of the danger theory. Interview by Lauren Constable, Commissioning Editor. Expert Rev. Clin. Immunol. 8, 311-317 (2012).
19. Matzinger P, Kamala T. Tissue-based class control: the other side of tolerance. Nat. Rev. Immunol. 11, 221-230 (2011).
20. Bachmann MF, McKall-Faienza K, Schmits R et al. Distinct roles for LFA-1 and CD28 during activation of naive T cells: adhesion versus costimulation. Immunity 7, 549-557 (1997).
21. Hahn WC, Rosenstein Y, Calvo V, Burakoff SJ, Bierer BE. A distinct cytoplasmic domain of CD2 regulates ligand avidity and T-cell responsiveness to antigen. Proc. Natl Acad. Sci. USA 89, 7179-7183 (1992).
22. Simpson TR, Quezada SA, Allison JP. Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Curr. Opin. Immunol. 22, 326-332 (2010).
23. Rudd CE, Schneider H. Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat. Rev. Immunol. 3, 544-556 (2003).
24. Kroenke MA, Eto D, Locci M et al. Bcl6 and Maf cooperate to instruct human follicular helper CD4 T cell differentiation. J. Immunol. 188, 3734-3744 (2012).
25. Choi YS, Kageyama R, Eto D et al. ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. Immunity 34, 932-946 (2011).
26. Boesteanu AC, Katsikis PD. Memory T cells need CD28 costimulation to remember. Semin. Immunol. 21, 69-77 (2009).
27. Hendriks J, Xiao Y, Rossen JW et al. During viral infection of the respiratory tract, CD27, 4-1BB, and OX40 collectively determine formation of CD8+ memory T cells and their capacity for secondary expansion. J. Immunol. 175, 1665-1676 (2005).
28. Stärck L, Scholz C, Dörken B, Daniel PT. Costimulation by CD137/4-1BB inhibits T cell apoptosis and induces Bcl-xL and c-FLIP (short) via phosphatidylinositol 3-kinase and AKT/protein kinase B. Eur. J. Immunol. 35, 1257-1266 (2005).
29. Munn DH, Sharma MD, Mellor AL. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J. Immunol. 172, 4100-4110 (2004).
30. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677-704 (2008).
31. Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111, 3635-3643 (2008).
32. McClory S, Hughes T, Freud AG et al. Evidence for a stepwise program of extrathymic T cell development within the human tonsil. J. Clin. Invest. 122, 1403-1415 (2012).
33. Starr TK, Jameson SC, Hogquist KA. Positive and negative selection of T cells. Annu. Rev. Immunol. 21, 139-176 (2003).
34. Ohnmacht C, Pullner A, King SB et al. Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. J. Exp. Med. 206, 549-559 (2009).
35. Kleindienst P, Chretien I, Winkler T, Brocker T. Functional comparison of thymic B cells and dendritic cells in vivo. Blood 95, 2610-2616 (2000).
36. Dzhagalov IL, Chen KG, Herzmark P, Robey EA. Elimination of self-reactive T cells in the thymus: a timeline for negative selection. PLoS Biol. 11, e1001566 (2013).
37. Derbinski J, Schulte A, Kyewski B, Klein L. Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat. Immunol. 2, 1032-1039 (2001).
38. Gotter J, Brors B, Hergenhahn M, Kyewski B. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J. Exp. Med. 199, 155-166 (2004).
39. Derbinski J, Gabler J, Brors B et al. Promiscuous gene expression in thymic epithelial cells is regulated at multiple levels. J. Exp. Med. 202, 33-45 (2005).
40. Anderson MS, Venanzi ES Chen Z et al. The cellular mechanism of AIRE control of T cell tolerance. Immunity 23, 227-239 (2005).
41. Xing Y, Hogquist KA. T cell tolerance: central and peripheral. Cold Spring Harb. Perspect. Biol. 4, pii: a006957 (2012).
42. Liston A, Lesage S, Wilson J, Peltonen L, Goodnow CC. AIRE regulates negative selection of organ-specific T cells. Nat. Immunol. 4, 350-354 (2003).
43. Koble C, Kyewski B. The thymic medulla: a unique microenvironment for intercellular self-antigen transfer. J. Exp. Med. 206, 1505-1513 (2009).
44. Gallegos AM, Bevan MJ. Central tolerance to tissue-specific antigens mediated by direct and indirect antigen presentation. J. Exp. Med. 200, 1039-1049 (2004).
45. Anderson MS, Su MA. AIRE and T cell development. Curr. Opin. Immunol. 23, 198-206 (2011).
46. Ruan QG, She JX. Autoimmune polyglandular syndrome type 1 and the autoimmune regulator. Clin. Lab. Med. 24, 305-317 (2004).
47. Martins I, Wang Y, Michaud M et al. Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ. doi:10.1038/cdd.2013.75 (2013) (Epub ahead of print).
48. Paulsen M, Janssen O. Pro- and anti-apoptotic CD95 signaling in T cells. Cell Commun. Signal 8, 7-9 (2011).
49. Bertolino P, Trescol-Biémont MC, Rabourdin-Combe C. Hepatocytes induce functional activation of naive CD8+ T lymphocytes but fail to promote survival. Eur. J. Immunol. 28, 221-236 (1998).
50. Zang YC, Li S, Rivera VM et al. Increased CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis. J. Immunol. 172, 5120-5127 (2004).
51. Martin R, Whitaker JN, Rhame L, Goodin RR, McFarland HF. Citrulline-containing myelin basic protein is recognized by T-cell lines derived from multiple sclerosis patients and healthy individuals. Neurology 44, 123-129 (1994).
52. Pisetsky DS. Antinuclear antibodies in healthy people: the tip of autoimmunity's iceberg? Arthritis Res. Ther. 13, 109 (2011).
53. Pavlovic M, Kats A, Cavallo M, Chen R, Hartmann JX, Shoenfeld X. Pathogenic and epiphenomenal anti-DNA antibodies in SLE. Autoimmune Dis. 2011, 462841 (2010).
54. Ding H, Nedrud JG, Blanchard TG et al. Th1-mediated immunity against Helicobacter pylori can compensate for lack of Th17 cells and can protect mice in the absence of immunization. PLoS ONE 8, e69384 (2013).
55. D'Argenio V, Precone V, Casaburi G et al. An altered gut microbiome profile in a child affected by Crohn's disease normalized after nutritional therapy. Am. J. Gastroenterol. 108, 851-852 (2013).
56. de la Cruz-Merino L, Carrasco FH, Baz DV et al. Immune microenvironment in colorectal cancer: a new hallmark to change old paradigms. Clin. Dev. Immunol. 2011, 174149 (2011).
57. Boon C, Dick T. How Mycobacterium TB goes to sleep: the dormancy survival regulator DosR a decade later. Future Microbiol. 7, 513-518 (2012).
58. Koebel CM, Vermi W, Swann JB et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450, 903-907 (2007).
59. Liang SC, Latchman YE, Buhlmann JE et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur. J. Immunol. 33, 2706-2716 (2013).
60. Keir ME, Latchman YE, Freeman GJ, Sharpe AH. Programmed death-1 (PD-1): PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes. J. Immunol. 175, 7372-7379 (2005).
61. Tipnis S, Viswanathan C, Majumdar AS. Immunosuppressive properties of human umbilical cord-derived mesenchymal stem cells: role of B7-H1 and IDO. Immunol. Cell Biol. 88, 795-806 (2010).
62. Abumaree MH, Chamley LW, Badri M, El-Muzaini MF. Trophoblast debris modulates the expression of immune proteins in macrophages: a key to maternal tolerance of the fetal allograft? J. Reprod. Immunol. 94, 131-141 (2012).
63. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
64. Hori J, Wang M, Miyashita M et al. B7-H1- induced apoptosis as a mechanism of immune privilege of corneal allografts. J. Immunol. 177, 5928-5935 (2006).
65. Rajasalu T, Brosi H, Schuster C et al. Deficiency in B7-H1 (PD-L1)/PD-1 coinhibition triggers pancreatic beta-cell destruction by insulin-specific, murine CD8 T-cells. Diabetes 59, 1966-1973 (2010).
66. Mozaffarian N, Wiedeman AE, Stevens AM. Active systemic lupus erythematosus is associated with failure of antigen-presenting cells to express programmed death ligand-1. Rheumatology (Oxford) 47, 1335-1341 (2008).
67. Trabattoni D, Saresella M, Biasin M et al. B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. Blood 101, 2514-2520 (2003).
68. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 24, 207-212 (2012).
69. Hamid O, Robert C, Daud A et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134-144 (2013).
70. Abramson J, Giraud M, Benoist C, Mathis D. AIRE's partners in the molecular control of immunological tolerance. Cell 140, 123-135 (2010).
71. Lehmann D, Ben-Nun A. Bacterial agents protect against autoimmune disease. I. Mice pre-exposed to Bordetella pertussis or Mycobacterium TB are highly refractory to induction of experimental autoimmune encephalomyelitis. J. Autoimmun. 5, 675-790 (1992).
72. Lee J, Reinke EK, Zozulya AL, Sandor M, Fabry Z. Mycobacterium bovis bacille Calmette-Guérin infection in the CNS suppresses experimental autoimmune encephalomyelitis and Th17 responses in an IFN-gamma-independent manner. J. Immunol. 181, 6201-6212 (2008).
73. Sewell DL, Reinke EK, Co DO et al. Infection with Mycobacterium bovis BCG diverts traffic of myelin oligodendroglial glycoprotein autoantigen-specific T cells away from the central nervous system and ameliorates experimental autoimmune encephalomyelitis. Clin. Diagn. Lab. Immunol. 10, 564-572 (2003).
74. Ben-Nun A, Mendel I, Sappler G, Kerlero de Rosbo N. A 12-kDa protein of Mycobacterium TB protects mice against experimental autoimmune encephalomyelitis. Protection in the absence of shared T cell epitopes with encephalitogenic proteins. J. Immunol. 154, 2939-2948 (1995).
75. Ristori G, Buzzi MG, Sabatini U et al. Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis. Neurology 53, 1588-1589 (1999).
76. Faustman DL, Wang L, Okubo Y et al. Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes. PLoS ONE 7, e41756 (2012).
77. Matzinger P. Essay 1: the danger model in its historical context. Scand. J. Immunol. 54, 4-9 (2001).
78. Honda K, Takada H, Nagatoshi Y et al. Thymus-independent expansion of T lymphocytes in children after allogeneic bone marrow transplantation. Bone Marrow Transplant. 6, 647-652 (2000).